There has been a dramatic increase in food allergy and other atopic conditions over the past decade or more, \[[@B1],[@B2]\] with the prevalence of peanut allergy increasing from 0.5% \[[@B3]\] a decade ago to between 1.0 and 1.8% \[[@B4]-[@B6]\]. Peanut allergy is the most common cause of fatal and near-fatal food-related anaphylaxis \[[@B7]-[@B9]\]. Parents with a peanut-allergic child often have a great deal of stress in attempting to ensure a peanut-free environment in the home, school, and play environments to prevent a life-threatening reaction \[[@B10]\]. A common question parents ask is whether there is an increased risk of a sibling also developing a life-threatening allergy to peanut.

Traditionally, allergists do not perform testing to foods before an individual has had an apparent adverse reaction to that food. The reason stems from the risk of finding sensitization to a food (ie, evidence of the presence of allergen-specific IgE) but not necessarily \"allergy\" (ie, having a systemic reaction). Routine \"panel testing\" to foods is not recommended by the American Academy of Allergy, Asthma and Immunology or the American College of Allergy, Asthma and Immunology. The rate of asymptomatic sensitization to foods in the general population can be as high as 30 to 50%, yet these individuals are not truly allergic \[[@B11]-[@B13]\].

We sought to determine whether there is an increased risk for a peanut-allergic child to have a sibling with a peanut allergy. We asked whether an allergy assessment by a qualified allergist of a younger sibling of a peanut-allergic child might be a prudent approach prior to that child\'s first anticipated exposure to peanut.

Methods
=======

The SAGE (Study of Asthma, Genes and the Environment) project is a case-control cohort study focused on the 1995 Manitoba Birth Cohort. Approximately 14,000 children were born in the province of Manitoba, Canada, and still living in the province in 2002. In 2001-2002, a child health and home environment questionnaire was sent to each household. It contained questions regarding the presence of asthma, food allergy, and other atopic conditions in the child. From the 3,615 returned surveys during 2003-2005, we assembled an asthma case-control cohort of 723 children (now aged 8-10 years).

In addition to a focus on asthma, a pediatric allergist (J.L. or A.B.) assessed the children for food allergy. With respect to food allergy, the clinical history included questions regarding the type of food identified, timeline of the reaction, symptoms of the reaction (eg, hives, cough, wheeze, diarrhea, vomit, loss of consciousness), severity of the reaction, and management of the reaction (ie, emergency room visit, antihistamines, epinephrine). The pediatric allergist clinical assessment for peanut allergy was blinded to skin testing and capRast results.

Skin testing to peanut (epicutaneous method) was performed on 603 children. Children sensitized to peanut had blood drawn for measurement of peanut-specific IgE by fluorenzymeimmunoassay (FEIA), generally known as capRAST. In consideration of the child\'s history (ie, severity of the initial reaction, presence of eczema or asthma), if the capRAST was sufficiently low (≤ 2.0 kUa/L), an oral food challenge was offered to determine true allergic status \[[@B14]\].

Index Cases of Peanut Allergy
-----------------------------

From among the children in the nested asthma case-control cohort (SAGE), a pediatric allergist diagnosed peanut allergy with current evidence of peanut-specific IgE (in vitro or in vivo) and/or failed peanut challenge for those children with low levels of peanut-specific IgE as noted above.

Sensitized but Not Peanut Allergic
----------------------------------

From among the children in the cohort, the child is skin test positive to peanut but able to tolerate peanut without an allergic reaction.

Index Controls (No Peanut Allergy)
----------------------------------

The child eats peanut products and is skin test negative.

Assessment of Siblings
----------------------

After assessment of index children, a survey was distributed to the parents of both cases and controls. This survey asked the following questions with regard to the index child\'s siblings: (1) Do your child\'s siblings have any food allergies? (please name the food). If yes, (i) Was he/she diagnosed by an allergist? (What is the allergist\'s name?); (ii) Was he/she skin tested to that food? (iii) Was a blood test sent for that food? (capRAST); (iv) Does he/she carry an epinephrine auto-injector (EpiPen or Twinject)?

Based on the questionnaire, diagnoses of peanut allergy were made as follows: parental report that the sibling has peanut allergy and that the child was assessed as peanut allergic by a board-certified allergist in the province of Manitoba in the past 5 years (10 allergists practiced in the province during that time), and the child currently carries an epinephrine auto-injector.

The allergists of those siblings were contacted to confirm the diagnosis of true peanut allergy; however, this was not a requirement for diagnosis. The study was approved by the Health Research Ethics Board at the University of Manitoba and the Health Information Privacy Committee of Manitoba.

Statistical Analysis
--------------------

Statistical analysis was performed with *SAS*software (SAS Institute, Cary, NC). Odds ratios with 95% confidence intervals (CIs) were calculated to determine the risk of a sibling of a peanut-allergic child having a peanut allergy when compared with the sibling of a non-peanut-allergic child. Children who were sensitized to peanut but not clinically allergic were excluded from analysis. Stratification by older versus younger sibling was performed. Multivariate analysis was performed to adjust for parental history of asthma. In the younger sibling stratification, adjustments were made for a physician diagnosis of asthma in the index child and parental history of asthma.

Results
=======

From the SAGE case-control cohort, 560 of 603 children tested to peanut were contacted to fill out the Sibling Food Allergy survey. Forty-three families had completed the primary study before this survey was introduced. Of 560 index families, 514 (92%) completed the survey. Twenty-nine (5.6%) index children were defined as peanut-allergic (cases), and eight index children were sensitized but not allergic. Four hundred fifty index children were not peanut allergic or sensitized (controls). The demographics of the cases and controls are shown in Table [1](#T1){ref-type="table"}. Table [2](#T2){ref-type="table"} shows the supporting test results to confirm peanut-allergic diagnoses in index children.

###### 

Demographics of Peanut and Non-Peanut-Allergic Children

  *Index Children*                           *Peanut Allergic*   *Non-Peanut Allergic*   *Sensitized*   *No Siblings*
  ------------------------------------------ ------------------- ----------------------- -------------- ---------------
  Number                                     29                  450                     8              27
  Male:female                                16:13               248:202                 5:3            18:9
  Urban:rural:FN                             20:8:1              247:160:43              0:6:2          18:9:0
  Parental history of asthma                 12                  150                     6              8
  Total number of siblings (older:younger)   47 (29:18)          853 (485:368)           9 (4:5)        \--

FN = First Nations.

###### 

Diagnoses of Peanut Allergy in Index Children (Cases)

  *Case*   *Peanut Skin-Prick Test Mean Wheal Diameter (mm)*   *Peanut-Specific IgE (kUa/L)*   *Oral Challenge to Peanut Butter\**   *Sibling with Peanut Allergy?*
  -------- --------------------------------------------------- ------------------------------- ------------------------------------- --------------------------------
  1        NA                                                  81.1                            NA                                    No
  2        NA                                                  5.2                             NA                                    No
  3        NA                                                  42.8                            NA                                    No
  4        13                                                  \> 100                          NA                                    No
  5        NA                                                  \> 100                          NA                                    No
  6        10                                                  \> 100                          NA                                    Yes
  7        9                                                   \> 100                          NA                                    Yes
  8        0                                                   \> 100                          NA                                    No
  9        7                                                   \> 100                          NA                                    Yes
  10       0                                                   1                               Failed oral challenge^†^              No
  11       5                                                   5.7                             NA                                    No
  12       6                                                   1.1                             Refused oral challenge                No
  13       4                                                   16.9                            NA                                    No
  14       5                                                   \> 100                          NA                                    No
  15       10                                                  29                              NA                                    No
  16       9                                                   41                              NA                                    No
  17       11                                                  \> 100                          NA                                    Yes
  18       10                                                  1.4                             Offered but lost to follow-up         No
  19       7                                                   0.8                             Failed oral challenge^†^              No
  20       8                                                   2.09                            NA                                    No
  21       17                                                  NA                              NA                                    No
  22       10                                                  \> 100                          NA                                    No
  23       8                                                   0.72                            Failed oral challenge^†^              No
  24       15                                                  80.2                            NA                                    No
  25       7                                                   \> 100                          NA                                    No
  26       8                                                   17.6                            NA                                    No
  27       6                                                   \< 0.35                         Lost to follow-up                     No
  28       8                                                   28.2                            NA                                    No
  29       10                                                  36.7                            NA                                    No

NA = not available.

\*In general, oral food challenges to peanut were offered to those with a capRast \< 2.0 kUa/L \[[@B14]\].

All children had a convincing history of peanut allergy prior to performing skin-prick testing ± capRAST.

^†^An oral challenge to peanut was performed in the hospital and the child had an adverse reaction.

Of the 514 index children, 27 did not have siblings. There were 900 siblings of the index children (excluding siblings of children who were sensitized to peanut but not allergic). Fifteen (1.7%) siblings had peanut allergy: 4 of 47 (8.5%) in the case group and 11 of 853 (1.3%) in the control group. Table [3](#T3){ref-type="table"} shows the evidence of peanut allergy in the siblings. We were able to confirm the diagnosis of peanut allergy in 14 of the siblings.

###### 

Peanut-Allergic Siblings of Index Children

  *Siblings of*   *Index Child Sibling from Table 2*   *Confirmed Diagnosis with Allergist\**   *Evidence of IgE SPT or capRast*
  --------------- ------------------------------------ ---------------------------------------- ----------------------------------------
  Cases                                                                                         
  1               6                                    Yes                                      capRast \> 100 kUa/L
  2               7                                    Yes                                      capRast \> 100 kUa/L
  3               9                                    Yes                                      capRast \> 100 kUa/L
  4               17                                   Yes                                      SPT mean wheal diameter 21 mm
  Controls                                                                                      
  1               NA                                   Yes                                      SPT mean wheal diameter 21 mm
  2               NA                                   Yes                                      capRast \> 100 kUa/L
  3               NA                                   Yes                                      Large SPT+ (no measurement recorded)
  4               NA                                   Yes                                      SPT mean wheal diameter 8 mm
  5               NA                                   Yes                                      capRast = 90.3 kUa/L
  6               NA                                   Yes                                      capRast = 22.8 kUa/L
  7               NA                                   Yes                                      SPT mean wheal diameter 14 mm
  8               NA                                   Yes                                      SPT: 4+ reaction (pseudopods)
  9               NA                                   No                                       Not confirmed
  10              NA                                   Yes                                      capRast \> 100 kUa/L
  11              NA                                   Yes                                      capRast = 2.3 kUa/L; no oral challenge

capRAST = FEIA for peanut-specific IgE; NA = not available; SPT = skin-prick test.

\*Allergist diagnosis included a definitive history of an adverse reaction to ingestion of peanut and evidence (in vivo or in vitro) of IgE toward peanut. Only control 9 was not confirmed.

Eight (1.5%) children were sensitized to peanut by skin-prick test but not allergic (able to eat peanuts without an adverse reaction). None of their siblings had a peanut allergy.

The odds ratio of a current peanut-allergic child at the age of 9 to 10 years having a sibling also with a peanut allergy is 7.12 (95% CI 2.18-23.28). After adjusting for a parental history of asthma, the odds ratio is 6.72 (95% CI 2.04-22.12) (Table [4](#T4){ref-type="table"}).

###### 

Risk of Peanut Allergy in Siblings of a Peanut-Allergic Child

  *Risk of Peanut Allergy in*   *Unadjusted Odds Ratio*   *95% CI*     *Adjusted Odds Ratio*   *95% CI*
  ----------------------------- ------------------------- ------------ ----------------------- ------------
  Any sibling                   7.12                      2.18-23.28   6.72\*                  2.04-22.12
  Younger sibling^†^            9.08                      1.63-50.40   11.76^‡^                2.46-56.27
  Older sibling^§^              5.92                      1.14-30.69   6.31\*                  1.20-33.23

CI = confidence interval.

\*Adjusted for parental history of asthma.

^†^If index child had a peanut allergy, risk of peanut allergy in a younger sibling.

^‡^Adjusted for parental history of asthma and physician diagnosis of asthma in index child.

^§^If older sibling had a peanut allergy, risk of peanut allergy in the index child.

If an older sibling of the index child had peanut allergy, the adjusted odds ratio of the index child having a peanut allergy is 6.31 (95% CI 1.20-33.23). If the index child had peanut allergy, the adjusted odds ratio of a younger sibling also having peanut allergy is 11.76 (95% CI 2.46-56.27).

Discussion
==========

Using a cohort study, we have shown that the sibling of a peanut-allergic child has a dramatically increased risk of developing peanut allergy. This risk is nearly 7-fold greater than those who do not have a sibling with peanut allergy, with an almost 12-fold increased risk for peanut allergy among younger siblings.

Emmett and colleagues examined the perceived prevalence of peanut allergy in Great Britain by using a screening survey followed by in-depth interviews with all reported sufferers from peanut allergy \[[@B15]\]. They estimated a peanut prevalence of 0.48%. Given one case in a household, the probability of another was estimated at 3.2%\--six times that in the United Kingdom (*p*\< .001). Nine of the 10 second cases in the same household were in first-degree relatives. They do not specify if these relatives were siblings. Our sevenfold increased risk is similar to their findings, except specifically for siblings.

Hourihane and colleagues examined the rates of atopic manifestations in people with peanut allergy and the prevalence of such allergy in their families by surveying 622 adults and children with reported, suspected, or known peanut allergy \[[@B16]\]. They evaluated 50 local children (mean age 5 years) with apparent peanut allergy and compared their results with those of a general population prevalence of peanut allergy (1.0-1.5%). In that study, the prevalence of peanut allergy in siblings of a peanut-allergic child was 7% (3 of 39). Sicherer and colleagues evaluated 58 twin pairs (median age of 5 years) ascertained through the Food Allergy Network \[[@B17]\]. They found a 64.3% pairwise concordance between monozygotic pairs and 6.8% concordance between dizygotic pairs. Our prevalence of 8.5% (4 of 47) among siblings is quite similar to both studies. Our study differs with the above two in that we studied a birth cohort of children all born in 1995 from across the province of Manitoba.

When we stratify our sibling cohort into younger and older siblings, we demonstrate that the younger sibling particularly has a very highly statistically significant increased risk for having a peanut allergy. Clearly, there is a genetic predisposition for peanut allergy in these families. Given the greater likelihood for a younger sibling having peanut allergy, we also question how much of a role the environment may play. As far as we are aware, there are no studies examining the impact of parental behaviour change with having a peanut-allergic child in the family. Intuitively, we would expect that parents will alter their behaviour to decrease exposure to peanut (ie, avoidance of peanut and tree nuts), particularly in the home environment. Of concern, recent human and animal literature suggests that avoidance of highly \"allergenic\" foods in pregnancy and early in life may actually predispose, as opposed to protect, a child to develop IgE-mediated food allergy \[[@B18]-[@B20]\].

Another finding from our study is the fact that 22% of children with positive skin testing to peanut (8 of 37 children) routinely had peanut without a problem. That is, these children were sensitized, but not truly allergic. This confirms other studies that have shown that a positive skin-prick test is only \"suggestive\" of the presence of a clinical peanut allergy \[[@B11]-[@B13]\]. A diagnosis of peanut allergy cannot be solely based on a skin-prick test but requires a proper clinical history or additional testing to corroborate the presence of true allergy. Although we agree that indiscriminate testing for peanut allergy should not be performed, based on our findings in this study, we recommend that siblings of peanut-allergic children should be assessed by a qualified allergist and, potentially, have appropriate skin testing.

Of note, two children in our cohort diagnosed by the pediatric allergist as allergic to peanut were skin test negative. One child had a strongly positive blood test for peanut-specific IgE (capRAST \> 100 kUa/L), and the other, with a positive but low level of peanut-specific IgE (capRAST of 1.0 kUa/L), failed an oral challenge. Neither of these children had a peanut-allergic sibling. This points out the value of measuring allergen-specific IgE in vitro (eg, capRAST) and performing proper food challenges as important tools to aid in the diagnosis of true food allergy \[[@B14]\].

Only one sibling (control 9) was unconfirmed by an allergist. However, the history was quite convincing of an IgE-mediated allergy to peanut allergy. If this sibling was not used in the analysis, the odds ratio would be even higher than that stated.

One limitation to our study is that we used the SAGE case-control cohort for this analysis. This is a high-risk cohort with respect to asthma as the purpose of the primary study is to investigate gene and environmental factors that may play a role in the development of asthma and allergy. Thus, our control group may be skewed toward being more allergic than the general population. Even so, these would be the patients one would expect to see in an allergy clinic. However, if the control group is biased toward an atopic predisposition, this may actually also overestimate peanut prevalence in the siblings of the control group. In spite of this, the prevalence of peanut allergy in our control group is similar to that reported in Canada and North America \[[@B5],[@B6]\].

Ideally, the oral food challenge is the best diagnostic test to determine true peanut allergy in children. In Manitoba, along with other aspects of history (ie, severity of initial reaction, presence of eczema or asthma), allergists use a capRAST value of \< 2.0 kUa/L to decide if a child should undergo an oral challenge \[[@B14]\]. Sampson found that a capRAST \> 15 kUa/L would provide a 95% predictive decision point to determine true allergy \[[@B21]\]. Thus, we realize that some of our index cases (eg, cases 2, 11, 12, 18, 20, and 27) and sibling control 11 may not be truly allergic. All of these children had good histories of an allergic reaction yet did not undergo an oral challenge. This is one limitation that may have overestimated our peanut prevalence.

A prospective long-term follow-up study of siblings of peanut-allergic children would be the best method to determine whether the skin test or capRAST should be used as a screening tool in siblings. One concern of screening siblings prior to feeding could cause either unnecessary avoidance or challenge procedures. Our study shows that there is an increased risk in peanut allergy in siblings of peanut-allergic children, which would suggest that screening of siblings is important. However, future studies should clarify proper cutoff points (for capRAST or skin-prick test wheal size) to aid in determination of risk of an oral challenge in these siblings.

In summary, we have shown that siblings of peanut-allergic children have a significantly increased risk of also developing a peanut allergy. We recommend that siblings born into a family with a peanut-allergic child be assessed for peanut allergy by a qualified allergist (who may perform skin-prick testing or measurement of allergen-specific IgE by capRAST or other technique) prior to being fed this food. An oral challenge in a controlled setting may be required. Future research must examine gene-environment interactions predisposing children to this increasingly common and potentially fatal food allergy.
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